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to the total number of screening procedures performed, colono-
scopies increased 60% (20% to 32%; p = 0.01), ﬂexible sig-
moidoscopy decreased 75% (8% to 2%; p = 0.01), barium
enema decreased 50% (2% to 1%; p = 0.01), and FOBT
decreased 6% (70% to 66%). Gastroenterologists performed an
increasingly large proportion of the colonoscopy procedures
(68% in 2000 vs. 73% in 2004). CONCLUSIONS: Colorectal
cancer screening in the private sector increased between 2000
and 2004. During this time, there was a substantial increase in
the use of colonoscopy and a marked decrease in the use of ﬂex-
ible sigmoidoscopy and barium enema. Additional research is
needed to track trends in these procedures and evaluate their
impact on health policy goals, patient outcomes, and system
capacity.
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OBJECTIVES: Epoetin alfa (EPO) and darbepoetin alfa (DARB)
are two erythropoietic stimulating therapies (ESTs) indicated for
the treatment of chemotherapy-induced anemia. This analysis
compared recent dosage patterns and associated drug costs of
EPO and DARB in hospitalized cancer patients. METHODS: An
analysis of electronic inpatient hospital records from the Premier
Perspective Comparative Hospital Database was conducted.
Study subjects were identiﬁed through hospitalizations recorded
between July 2002 and March 2005 from over 500 hospitals
nationwide. Included were patients ≥18 years of age with a
primary admitting diagnosis of cancer who were treated with
EPO or DARB during their hospital stay. Patients who had
received renal dialysis were excluded. To minimize effect of out-
liers, 5% of patients with extreme doses in each group were
excluded from the dosing analysis. Wholesale acquisition costs
in 2005 (EPO: $0.01217/Unit, DARB: $4.36/mcg) were used to
calculate EST costs. RESULTS: A total of 27,804 patients were
identiﬁed (EPO: 24,814, DARB: 2990). Mean age and gender
distribution were comparable between groups (age: EPO 65.3
years, DARB 64.5 years; % women: EPO 53%, DARB 55%).
Mean cumulative dose per inpatient stay was EPO 61,656 ±
50,274 Units and DARB 259 ± 340mcg, corresponding to a dose
only ratio of 238 :1 (Units EPO: mcg DARB). Average treatment
cost was signiﬁcantly lower in the EPO group, compared to
DARB (EPO: $750, DARB: $1129; p < 0.0001). CONCLU-
SION: This analysis utilizing inpatient data demonstrated a dose
only ratio between EPO and DARB of 238 :1 in patients with
cancer. DARB was found to cost 51% more than EPO based on
the cumulative dose administered during hospitalization.
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OBJECTIVES: The objective of this study was to determine
incremental direct expenditures of treating hypertension in the
U.S. non-institutionalized population. METHODS: Analysis of
2001 Medical Expenditure Panel Survey (MEPS) data, a national
probability sample survey of 33,556 individuals from the civil-
ian non-institutionalized U.S. population was conducted. Hyper-
tensive patients were identiﬁed as those with hypertension based
ICD-9 codes, i.e., 401-xx-405-xx for medical conditions or
medical events, including inpatient visits, outpatient visits, emer-
gency room visits, home-health visits, ofﬁce-based medical
provider visits, and other medical expenses, or patients who self-
reported being diagnosed with hypertension by their physician,
or patients who were prescribed an anti-hypertensive medication
listed in seventh report of the Joint National Committee on Pre-
vention, Detection, Evaluation, and Treatment of Hypertension,
unless there was an indication that the medication was pre-
scribed for a medical condition other than hypertension. Only
individuals 18 years of age or older were included. Incremental
expenditures for treating hypertension were estimated through
least squares regression adjusting for age, gender, race, educa-
tion, and co-morbidities using the D’Hoore version of the Charl-
son co-morbidity index. Sample data were projected to the U.S.
population and 95% conﬁdence limits for estimates were calcu-
lated using the Taylor expansion method. RESULTS: Sample
estimates projected to the population indicated that approxi-
mately 17.4% of individuals aged 18 years and above in the
ambulatory population have hypertension. Total incremental
annual direct expenditures for hypertension patients were esti-
mated to be more than $US 54.0 billion in 2001 after adjusting
for demographics and co-morbidities. Mean incremental annual
direct expenditures for an individual with hypertension was $US
1131. Prescription medicines, inpatient visits, and outpatient
visits constituted more than 90% of overall incremental expen-
ditures. CONCLUSIONS: With incremental direct medical
expenditures estimated at nearly $US55.0 billion, hypertension
expenditures represent a signiﬁcant amount of health care
resource utilization.
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OBJECTIVES: To determine the impact of ventricular arrhyth-
mia on mortality and health care resource utilization in hospi-
talized patients with acute myocardial infarction (AMI).
METHODS: A retrospective cohort study design was used.
Adult patients with primary diagnosis of AMI (ICD-9 code:
410.x1), between July 2003 and June 2004, were identiﬁed from
a large retrospective database of 800 hospitals in the United
States. The AMI patients were further classiﬁed based on sec-
ondary diagnosis of ventricular arrhythmia into three groups:
AMI with sustained ventricular tachycardia (sustained VT)/ven-
tricular ﬁbrillation (VF) (ICD-9 code: 427.4x, 427.5); AMI with
paroxysmal ventricular tachycardia (PVT) (ICD-9 code 427.1);
and AMI without ventricular arrhythmia. Mortality rates, length
of hospital stay and cost were compared between the groups
using chi-square and ANOVA tests. RESULTS: A total of 91,225
patients with primary diagnosis of AMI were identiﬁed, of which
8125 (8.9%) patients had a secondary diagnosis of ventricular
arrhythmia, including sustained VT/VF (N = 3004; 3.3%) and
PVT (N = 5121; 5.6%). A majority of the AMI patients with
ventricular arrhythmia were male (70.2%), caucasian (73.4%)
and ≥65 years (55%). In-hospital mortality rates were higher in
the AMI patients with sustained VT/VF (28.5%) and PVT
(7.9%), than AMI patients without ventricular arrhythmia
(6.2%). The average hospital length of stay was signiﬁcantly
higher (p < 0.001) in AMI patients with sustained VT/VF (8.0 ±
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9.8 days) and PVT (7.7 ± 8.4days), compared with AMI patients
without ventricular arrhythmia (5.5 ± 6.1 days). Average hospi-
talization costs were signiﬁcantly higher (p < 0.001) in AMI
patients with sustained VT/VF ($26,524 ± 29,869) and PVT
($23,447 ± 27,704) than those for AMI patients without ven-
tricular arrhythmia ($14,449 ± 16,638). CONCLUSIONS: Ven-
tricular arrhythmia in AMI patients was associated with higher
mortality and increased resource utilization. Prevention of ven-
tricular arrhythmia in AMI patients would potentially yield ben-
eﬁts of increased survival and reduced costs.
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OBJECTIVES: The objective of this study was to examine 
prescribing patterns of lipid lowering agents among Medic-
aid/Medicare dual eligible patients by ethnicity. METHODS:
Data came from the Thomson Medstat Marketscan® Medicare
and Medicaid claims databases. Beneﬁciaries who were pre-
scribed these agents during 2003 and enrolled for the full year
in both databases were in the study sample. Logistic regression
models estimated the probability of a switch, augmentation, or
titration up, by ethnicity. Switching was a change in the agent,
augmentation was at least 30 days of overlapping therapy, and
titration upwards was an increase in dosage for two consecutive
prescriptions. RESULTS: There were 239,530 patients included
in the study. Fewer African Americans (9%) switched lipid low-
ering agents than Asians, Hispanics, Caucasians or other eth-
nicities (14%, 13%, 12%, and 13%, respectively) did. Fewer
African Americans (3%) augmented with another agent than
Asians, Hispanics, Caucasians or others (6%, 5%, 6% and 5%).
Logistic regressions showed that African Americans were signif-
icantly less likely to switch (OR 0.68; 95% CI 0.60–0.78),
augment (OR 0.53; 95% CI 0.43–0.66), or titrate up (OR 0.75;
95% CI 0.67–0.84) than Caucasians, controlling for age, gender,
state of residence, days on therapy, number of outpatient visits,
and the Chronic Disease Score. CONCLUSIONS: Results were
consistent with the literature which shows lipid lowering agent
prescribing for African Americans tended to be less aggressive,
as evidenced by fewer switches, less augmentation and less
upward titration. This may reﬂect treatment differentials such as
clinicians being less likely to increase doses of lipid lowering
agents to help these patients reach goal. It may also reﬂect the
effectiveness of these agents in lowering lipid levels and keeping
patients at consistently low levels. These treatment issues merit
further observation as dual eligibles move into Medicare part D
plans with differing coverage and formulary restrictions.
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OBJECTIVES: Examine use and cost of inpatient, emergency
department (ED), and observation unit (OU) services during one
year by patients treated for congestive heart failure (CHF).
METHODS: Using 2001–2002 Massachusetts hospital, ED and
OU data, a cohort of adult patients (age: 18+ years) with CHF
(ICD-9 principal diagnosis code: 428.0–428.9) was identiﬁed. A
patient CHF encounter proﬁle was established starting with the
ﬁrst stay/visit (index encounter) at any hospital, ED or OU in
2001 and included all subsequent inpatient, ED or OU care for
CHF within 12 months. Charges (accommodations, ancillary
services) adjusted by a 0.55 cost-to-charge ratio, medical inﬂa-
tion and geographic factors are reported as 2005 US$ costs.
RESULTS: The patient cohort (n: 18,550; females: 56%; mean
age: 61 years, range: 18–104) used a combined total of 28,673
CHF-related hospitalizations, ED and OU stays during one year
(mean encounters: 1.5, range: 1–29). Of all encounters, 84%
were inpatient, 12% ED and 4% OU. Only inpatient care was
used by 79% of the cohort (mean stays: 1.4, range: 1–16); 8%
ED only (mean visits: 1.1, range: 1–19); 3% OU only (mean
stays: 1.1, range: 1–3); 9% used multiple care settings (mean
encounters: 3, range: 2–12); and 1% used all (mean encounters:
5.2, range: 3–29). Patients with inpatient plus ED or OU care
had a signiﬁcantly (p < 0.01) greater readmission rate (44%) for
CHF than those utilizing only inpatient care (26%). On average,
hospital length of stay was 5.4 days, cost: $7736; ED visit: 4.7
hours, cost: $740; OU stay: 29 hours, cost: $2468, per encounter.
Cumulative cost for hospital, ED and OU care for one year was
roughly $190 million. CONCLUSIONS: Inpatient care was the
dominant non-routine setting for acute management of CHF.
Those utilizing multiple acute care locations are more likely to
have multiple hospitalizations within one year.
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OBJECTIVES: Prior authorization (PA), the requirement of
physicians to obtain pre-approval as a prerequisite for coverage
may decrease drug utilization via a “sentinel effect”, a decrease
in utilization caused by external review of prescribing. The
purpose of this study was to assess the affect a PA restriction had
on the utilization patterns of cefuroxime tablets in a Managed
Care Organization (MCO) in Israel. METHODS: Prescribing
patterns were evaluated from electronic patient records. A ret-
rospective drug-utilization analysis was conducted. All prescrip-
tions for solid state antibiotics for patients diagnosed with an
infectious disease during three parallel, three month segments:
before, during, and after a PA restriction for cefuroxime was
enforced were included. Frequency and proportion of antibiotic
prescriptions for cefuroxime, distribution of infectious diseases
treated with cefuroxime, and the request rejection rate when PA
was required were calculated. RESULTS: Prescription of
cefuroxime declined from 5538 (8.0% of eligible antibiotic pre-
scriptions, 95% CI = 7.8, 8.2) in the initial period to 1036
(1.2%, 95% CI = 1.1, 1.3) during the PA period, rising to 3961
(4.3%, 95% CI = 4.2, 4.4) in the post-PA period. Changes in the
distribution of diseases treated with cefuroxime during the PA
stage tended to regress after revocation to those observed in 
the pre-PA period. The rejection rate was 8.5% (95% CI =
6.9–10.1). CONCLUSIONS: Although a PA requirement for
cefuroxime markedly reduces utilization probably due to a “sen-
tinel effect”, it will not lead to residual effects on prescribing
behavior upon its revocation, indicating the need for a multi-
pronged approach in the realm of policy, regulation and man-
agement regarding prescribing behavior. While many articles
have alluded to the need to create a “culture of quality”, we
